Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30712765 | 1.00 | KMT2A (0.47) | KMT2AOPRD1ALDH1A1EPHX2CYP3A4 | |
| SCHEMBL30918231 | 1.00 | KMT2A (0.47) | KMT2AOPRD1ALDH1A1EPHX2CYP3A4 | |
| SCHEMBL29101925 | 1.00 | KMT2A (0.47) | KMT2AOPRD1ALDH1A1EPHX2CYP3A4 | |
| SCHEMBL30620557 | 0.92 | KMT2A (0.43) | KMT2AOPRD1ALDH1A1EPHX2CASP3 | |
| SCHEMBL30712760 | 0.92 | KMT2A (0.43) | KMT2AOPRD1ALDH1A1EPHX2CASP3 | |
| SCHEMBL30918284 | 0.90 | PTPN1 (0.45) | OPRD1PTPN1 | |
| SCHEMBL30918202 | 0.90 | PTPN1 (0.45) | OPRD1PTPN1 | |
| SCHEMBL29101923 | 0.89 | KMT2A (0.50) | KMT2AOPRD1EPHX2CASP3 | |
| SCHEMBL30918204 | 0.88 | CTSB (0.48) | PTPN1 | |
| SCHEMBL31089971 | 0.87 | OPRD1 (0.45) | OPRD1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001891-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | KEYMED BIOSCIENCES (CHENGDU) CO., LTD. (CN) | 2026-01-01 | — | — | US | disclosed |
| EP-4623936-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | Keymed Biosciences (Chengdu) Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025100975-A1 | CARRIER-DRUG CONJUGATE COMPRISING HETEROGENEOUS DRUGS AND METHOD FOR PREPARING SAME | 주식회사 피노바이오 | 2025-05-15 | — | — | WO | disclosed |
| US-20240293569-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATE | PINOTBIO, INC. (KR) | 2024-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293569-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATE | BCR, IGSF11, STT3B | KMT2A 560/4885OPRD1 3956/4885ALDH1A1 1174/4885 |
| US-20260001891-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | HCCS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1 | KMT2A 3084/4885OPRD1 307/4885ALDH1A1 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.